We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current NXS market cap is 109.39M. The company's latest EPS is USD -0.0558 and P/E is -6.63.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 4.1M | 3.8M | 9.09M | 11.75M | 22.28M |
| Operating Income | -12.5M | -12.19M | -9.47M | -12.7M | -15.95M |
| Net Income | -14.35M | -11.91M | -9.35M | -12.68M | -16.27M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 22.7M | 23.64M | 13.72M | 12.46M | 17.9M |
| Total Liabilities | 3.34M | 4.73M | 2.95M | 4.42M | 5.08M |
| Total Equity | 19.36M | 18.91M | 10.77M | 8.04M | 12.82M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -12.33M | -11.91M | -8.26M | -11.79M | -15.06M |
| Investing | -1.61M | -687k | -716k | -476k | -885k |
| Financing | 23.69M | 10.71M | 1.43M | 10.25M | 20.11M |
| Market Cap | 109.39M |
| Price to Earnings Ratio | -6.63 |
| Price to Sales Ratio | 4.84 |
| Price to Cash Ratio | 11.67 |
| Price to Book Ratio | 8.42 |
| Dividend Yield | - |
| Shares Outstanding | 291.7M |
| Average Volume (1 week) | 85.75k |
| Average Volume (1 Month) | 199.17k |
| 52 Week Change | -36.97% |
| 52 Week High | 0.665 |
| 52 Week Low | 0.18 |
| Spread (Intraday) | 0.05 (12.5%) |
| Company Name | Next Science Limited |
| Address |
level 14 sydney, new south wales 2000 |
| Website | https://www.nextscience.com/ |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
